Effect of Oxytocin on Sexual Well-Being and Intimacy in Patients with Vasopressin Deficiency [Central Diabetes Insipidus] and Healthy Controls
Zusammenfassung der Studie
Patients with a vasopressin deficiency (central diabetes insipidus) suffer from a lack of the antidiuretic hormone vasopressin. These patients produce a high amount of urine and must compensate for this fluid loss with a high intake of fluids. Desmopressin, a medication similar to vasopressin, can be used to treat this condition. Despite treatment with desmopressin, patients often report symptoms such as increased anxiety, reduced trust, a lower sense of closeness and security, decreased sexual desire, and an overall reduced quality of life. A recent study has shown that these patients lack not only the hormone vasopressin but also the hormone oxytocin. In the brain, oxytocin is produced in the same area as vasopressin and released from the pituitary gland. The hormone is involved in important positive psychosocial aspects such as building trust, closeness, and love, has anxiolytic effects, positively influences sensations such as relaxation, and enhances empathy. This hormone is therefore also referred to as the cuddle, love, or loyalty hormone. The observed psychological changes in patients could therefore be partially explained by this additional oxytocin deficiency. In this study, we investigate whether the administration of the study medication oxytocin over a period of one week leads to an improvement in sexual well-being and intimacy in patients. This includes sexual arousal, orgasm ability, sexual satisfaction, and partner bonding.
(BASEC)
Untersuchte Intervention
This study is a so-called cross-over study, meaning all participants will receive a placebo on two study days and oxytocin as a nasal spray on two study days. The order of the study days is determined randomly. The placebo contains no active ingredient and is thus a 'dummy medication'. After the preliminary examination, a total of four study appointments will take place:
• On two of these study days at home, the effect of the sprays on your sexual arousal, satisfaction, and intimacy after sexual interaction will be investigated.
• On the other two study days on-site, specific emotions such as sexual arousal, empathy, and stress/anxiety will be tested in response to various film clips.
(BASEC)
Untersuchte Krankheit(en)
Patients with Vasopressin Deficiency (Central Diabetes Insipidus)
(BASEC)
Inclusion Criteria for Healthy Controls 1. Healthy volunteers 2. Same age, gender, BMI, and menopause/hormonal contraception as the patients. 3. No medications, except hormonal contraception Patients: 1. Confirmed diagnosis of AVP deficiency according to established criteria 2. Stable hormone therapy for at least three months with desmopressin and, in cases of additional anterior pituitary insufficiencies, with the corresponding substitution therapies 3. At least a mild impairment of sexual function and satisfaction, defined as an ASEX score of ≥10 points and an NSSS-S score of ≤48 points (BASEC)
Ausschlusskriterien
1. Pregnancy and breastfeeding within the last eight weeks 2. Active substance use disorder within the last six months 3. Consumption of alcoholic beverages >15 drinks/week 4. Acute or previous psychotic disorder (e.g., schizophrenia) 5. Prolonged QTc interval (>470ms) in a 12-lead electrocardiogram (BASEC)
Studienstandort
Basel
(BASEC)
Sponsor
Mirjam Christ-Crain
(BASEC)
Kontakt für weitere Auskünfte zur Studie
Kontaktperson Schweiz
Mirjam Christ-Crain
0612652525
mirjam.christ-crain@clutterusb.chDept. of Endocrinology, Metabolism & Diabetes University Hospital Basel Petersgraben 4 4031 Basel
(BASEC)
Wissenschaftliche Auskünfte
nicht verfügbar
Name der bewilligenden Ethikkommission (bei multizentrischen Studien nur die Leitkommission)
Ethikkommission Nordwest- und Zentralschweiz EKNZ
(BASEC)
Datum der Bewilligung durch die Ethikkommission
03.01.2025
(BASEC)
ICTRP Studien-ID
nicht verfügbar
Offizieller Titel (Genehmigt von der Ethikkommission)
Effects of intranasal Oxytocin on Sexual Well-Being in Patients with Arginine Vasopressin Deficiency (central Diabetes insipidus) and Healthy Controls- the OxyPLEASURE Study (BASEC)
Wissenschaftlicher Titel
nicht verfügbar
Öffentlicher Titel
nicht verfügbar
Untersuchte Krankheit(en)
nicht verfügbar
Untersuchte Intervention
nicht verfügbar
Studientyp
nicht verfügbar
Studiendesign
nicht verfügbar
Ein-/Ausschlusskriterien
nicht verfügbar
nicht verfügbar
Primäre und sekundäre Endpunkte
nicht verfügbar
nicht verfügbar
Registrierungsdatum
nicht verfügbar
Einschluss des ersten Teilnehmers
nicht verfügbar
Sekundäre Sponsoren
nicht verfügbar
Weitere Kontakte
nicht verfügbar
Sekundäre IDs
nicht verfügbar
Angaben zur Verfügbarkeit von individuellen Teilnehmerdaten
nicht verfügbar
Weitere Informationen zur Studie
nicht verfügbar
Ergebnisse der Studie
Zusammenfassung der Ergebnisse
nicht verfügbar
Link zu den Ergebnissen im Primärregister
nicht verfügbar